Platelet-activating factor (PAF) is a naturally occurring phospholipid that acts as a pleiotropic mediator of inflammation via specific membrane receptors. It has been demonstrated in recent years that PAF is a strong secretagogue of mucous glycoprotein (MGP) in airways and middle ear epithelium. MGP secretion accompanies otitis media with effusion (OME) and prolongs the course of this disease by increasing the viscoelasticity of the fluid. It is important, therefore, to inhibit the pathological secretion of MGP in the treatment of otitis media. In the current study, we investigated the effects of PAF receptor inhibitor WEB 2170 BS on in vitro MGP secretion. At concentrations of 100 mu M, PAF significantly stimulated MGP secretion. WEB 2170 BS significantly inhibited this PAF-simulated MGP secretion at concentrations of 2000 mu M. The action of WEB 2170 BS was concentration-dependent. However, it did not affect MGP secretion stimulated by IL-1beta, suggesting that WEB 2170 BS inhibits PAF-stimulated MGP secretion, specifically. It was noted that WEB 2170 BS did not completely eliminate MGP secretion induced by PAF even though a high concentration was used. The fact that WEB 2170 BS alone does not exhibit an inhibitory or stimulatory effect on the secretion of MGP suggests that WEB 2170 BS competitively binds to PAF receptors and possesses less affinity to PAF receptors than PAF.